ARVN compared with XERS: revenue, margins and what each company keeps, and the suppliers and customers both name

ARVNArvinas, Inc.

Mkt capRevenueRevenue

XERSXeris Biopharma Holdings, Inc.

Mkt capRevenueRevenue

Compare

ARVNArvinas, Inc.

XERSXeris Biopharma Holdings, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ARVN

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±29.4%▼−5.72%×0.19

Q2 FY26±9.0%▲+11.66%×1.30

May 12 '26±8.5%▼−0.93%×0.11

Q1 FY26±22.1%▲+0.57%×0.03

XERS

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±15.0%▲+25.05%×1.67

Q2 FY26±14.3%▼−9.25%×0.65

= impliedARVN realized, solidXERS realized, hatchedOne scale, both sides: full bar = 30%× = |realized| ÷ impliedSource: market data

May 7 '26

±12.7%

▲+4.08%

×0.32

Q1 FY26±21.8%▼−1.63%×0.07

ARVNArvinas, Inc.

6.41▼−2.14%· post 6.41

Mkt cap$419.8MRevenue$500,000Q3 FY26Revenue$263MFY25

XERSXeris Biopharma Holdings, Inc.

15.20▲+16.17%· post 15.12

ClosedNov 6 '26

Mkt cap$2.8BRevenue$107MQ3 FY26Revenue$292MFY25

Compare

ClosedNov 6 '26

ARVNArvinas, Inc.

XERSXeris Biopharma Holdings, Inc.

6.41▼−2.14%post 6.41

Price

15.20▲+16.17%post 15.12

$419.8M

Mkt cap

$2.8B

Q3 FY26$500,000

Revenue

$107MQ3 FY26

FY25$263M

Revenue

$292MFY25

ARVN6.41▼−2.14%vsXERS15.20▲+16.17%ClosedNov 6 '26